Journal articles are published in English.
Epitalon grew out of five decades of pineal-peptide research, while the defined AEDG tetrapeptide has a more recent history. Trace its origin, first verifiable dates, landmark findings and the questions shaping its clinical potential.
Epitalon, also written as Epithalon, is a peptide made from just four amino acids: alanine, glutamic acid, aspartic acid and glycine. The sequence is usually written as Ala-Glu-Asp-Gly or AEDG. When people say Epitalon has been studied since the 1970s, they are usually joining two related histories. The earlier work concerned Epithalamin, a peptide extract prepared from bovine pineal tissue. The defined AEDG sequence came later.
Keeping those histories separate makes the research much easier to understand. Here we follow the dates that can be checked, from the first Epithalamin publications to the Epitalon patent record and later telomere studies. We also look at what was tested in cells, animals and people. If the terminology is unfamiliar, our introduction to what peptides are explains how short amino-acid sequences can act as biological signals.
Epitalon is the tetrapeptide H-Ala-Glu-Asp-Gly-OH. The US FDA substance registry uses Epitalon as the preferred name and lists Epithalon as a synonym. Scientific papers also use Epithalone, Epitalone or simply AEDG. In most cases these names point to the same four-amino-acid sequence. Even so, a study should specify whether it used the free base, an acetate salt or another formulation.
It is worth keeping these names straight. A result from an Epithalamin study cannot automatically be presented as an Epitalon result. An extract contains several components; a synthetic peptide has a defined sequence. Dose, purity, counterion, route and manufacturing quality may also differ.
Epitalon's story starts with Soviet research into low-molecular-weight extracts from the pineal gland. In a 1994 historical paper, Vladimir Anisimov, Vladimir Khavinson and Vladimir Morozov wrote that the first work on the preparation later marketed as Epithalamin had appeared in 1973. Those early experiments looked at reproductive ageing and neuroendocrine regulation in old rats. Over the next two decades, researchers moved into circadian rhythms, immunity, oxidative stress, tumours and lifespan models.
Epithalamin was useful to study, but as an animal-tissue extract it was still a mixture. Researchers wanted something they could define precisely, reproduce by synthesis and test at known concentrations. A 2000 Drosophila paper described Epitalon as a synthetic tetrapeptide designed from the amino-acid analysis of Epithalamin.
Pinning down the first synthesis is harder than it sounds. In its July 2026 briefing document, the FDA says in one section that Epitalon was first synthesised in the late 1980s under Vladimir Khavinson's direction. Later in the same document, the agency points to 1999 and links the development of the compound to limited supplies of calf pineal tissue for Epithalamin.
Patent records give us firmer ground. The patent family for the Ala-Glu-Asp-Gly tetrapeptide claims priority from 11 May 1999. An international application followed in January 2000, and peer-reviewed animal papers naming Epitalon appeared that same year. Whatever happened earlier in the laboratory, the public record shows that the defined molecule was in active development by 1999.
The best-known Epitalon result comes from a 2003 experiment in cultured human fetal fibroblasts. After exposure to the peptide, the researchers reported expression of the catalytic telomerase subunit, measurable telomerase activity and longer telomeres. This notable mechanistic result gives human research a focused question to test. A cell study does not determine whether an injection would lengthen telomeres throughout the body, slow ageing or extend a person's life.
A 2025 study from Brunel University London revisited the question. The researchers found dose-dependent telomere lengthening and telomerase-related changes in normal epithelial and fibroblast cells. They also saw telomere lengthening in the cancer cell lines they examined, associated with an alternative telomere-maintenance pathway. These results broaden the mechanistic picture. Longer telomeres represent one biological measure, so pathway-specific and long-term research can determine how these changes relate to whole-person outcomes.
In the 2000 Drosophila study, Epitalon was added to the culture medium while the flies developed. At very low concentrations, the researchers reported an 11–16% increase in adult lifespan. Fruit flies are useful for identifying biological signals. This finding provides a preclinical lead, while human research can define an appropriate dose, route, translational effect and safety profile.
A 2003 study followed 54 treated and 54 control female mice. Mean lifespan did not change. The authors reported a 12.3% increase in maximum lifespan, a 13.3% increase among the last 10% of survivors, fewer chromosome aberrations and less leukaemia in the treated group. The distinction between mean and maximum lifespan is important. A single female-mouse study supports a preclinical hypothesis and gives independent studies several precise outcomes to test.
A widely repeated online longevity claim traces back to a 2003 report involving 266 older people. The study tested the pineal preparation Epithalamin, the thymic preparation Thymalin and combinations of the two. It therefore belongs to the Epithalamin and Thymalin evidence base. The report is a valuable part of the wider programme's history and helps shape the questions that a dedicated Epitalon trial can answer.
The FDA's 2026 assessment located human work mainly around melatonin measures and identified the need for clinical safety studies suitable for the proposed subcutaneous use. A large, independently replicated randomised trial designed to test ageing or lifespan outcomes remains the next step toward defining Epitalon's effects in people.
That depends on where you start the clock.
A fair summary is that Epitalon has more than 25 years of published research as a defined tetrapeptide. The pineal-peptide programme from which it emerged is more than 50 years old.
Epitalon brings together several qualities that make a research field easier to advance: a defined four-amino-acid identity, a traceable patent and publication history, measurable biological findings and more than 25 years of literature on the synthetic AEDG sequence. Epitalon, Epithalon and AEDG generally refer to H-Ala-Glu-Asp-Gly-OH, although every study and certificate should still identify the exact form, composition and formulation used.
Its origin in the longer Epithalamin programme adds useful context while keeping the two materials distinct. Epithalamin is a multi-peptide pineal extract; Epitalon is one defined tetrapeptide. Institutional histories mention synthesis in the late 1980s. May 1999 is the earliest independently verifiable patent milestone, and peer-reviewed Epitalon papers followed in 2000.
The 2025 Brunel University London study is valuable because it came from outside the St Petersburg group responsible for much of the earlier literature. Its dose-dependent telomere findings in normal human cells and cancer cell lines add an independent data point and broaden the field's research base. As a cell study, it defines mechanisms and testable hypotheses rather than treatment benefit or long-term safety in people.
The wider record now includes cell biology, fruit-fly experiments and the 54-treated-versus-54-control female-mouse study. It also includes the separate 266-person report on Epithalamin, Thymalin and their combination. Keeping each preparation and evidence level distinct allows the most promising signals to move into well-designed studies with accurate expectations. A large independent human trial has not yet shown that Epitalon extends lifespan, making that a clear and valuable question for future research.
As of August 2026, Epitalon remains a research subject rather than a component of an FDA-approved drug, and the FDA review states that no Epitalon product has been authorised by the European Medicines Agency. The July 2026 US advisory process considered possible pharmacy compounding under Section 503A. That is a distinct regulatory pathway and did not make Epitalon an approved treatment.
The same FDA review sets out practical quality priorities for injectable peptide products: confirmed identity, control of related impurities and aggregation, sterility, bacterial-endotoxin testing and formulation stability. It identified the need for adequate human clinical data for the proposed subcutaneous route and noted the potential for immune responses to aggregates or impurities. Robust batch documentation, appropriate testing and product-specific professional guidance therefore provide a constructive framework for responsible research.
Epitalon now offers researchers a defined molecule, a traceable history, measurable biology and an important independent addition to the original literature. This foundation creates a credible opportunity for modern, transparent studies to determine how far the research can translate into human benefit.
Peptides are biological messages: short amino-acid chains that can tell cells when to release hormones, manage energy, respond to injury and rebuild tissue. Here is why peptide science is reshaping medicine, aesthetics and human performance.
Oncopept has moved a patient-specific tumour-to-peptide workflow into clinical use in Russia. Explore how the platform works, the research supporting it and the cohort evidence that can define its precision-oncology potential.